Galectin Therapeutics (GALT) to Release Quarterly Earnings on Friday

Galectin Therapeutics (NASDAQ:GALT) is projected to post its quarterly earnings results before the market opens on Friday, April 4th. Analysts expect Galectin Therapeutics to post earnings of ($0.16) per share for the quarter.

Galectin Therapeutics Price Performance

Shares of NASDAQ GALT opened at $1.68 on Friday. Galectin Therapeutics has a 1 year low of $0.73 and a 1 year high of $4.27. The company has a market capitalization of $105.44 million, a price-to-earnings ratio of -2.30 and a beta of 0.69. The business has a 50-day moving average of $1.45 and a two-hundred day moving average of $1.99.

Wall Street Analyst Weigh In

GALT has been the subject of a number of research analyst reports. HC Wainwright reissued a “neutral” rating on shares of Galectin Therapeutics in a research report on Friday, December 27th. StockNews.com downgraded Galectin Therapeutics from a “hold” rating to a “sell” rating in a report on Monday, December 30th.

Institutional Trading of Galectin Therapeutics

A hedge fund recently raised its stake in Galectin Therapeutics stock. Bank of America Corp DE grew its position in Galectin Therapeutics Inc. (NASDAQ:GALT) by 101.4% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 38,358 shares of the company’s stock after buying an additional 19,316 shares during the quarter. Bank of America Corp DE owned 0.06% of Galectin Therapeutics worth $49,000 at the end of the most recent quarter. Institutional investors and hedge funds own 11.68% of the company’s stock.

Galectin Therapeutics Company Profile

Galectin Therapeutics Inc, a clinical stage biopharmaceutical company, engages in the research and development of therapies for fibrotic, cancer, and other diseases. Its lead product candidate is belapectin (GR-MD-02) galectin-3 inhibitor, that is in Phase 2b/3 clinical trial, to prevent esophageal varices in patient with non-alcoholic steatohepatitis (NASH) cirrhosis; and Phase 2 clinical trial for the treatment of liver fibrosis, as well as severe skin disease, and melanoma and head and neck squamous cell carcinoma.